Literature DB >> 1601530

A distribution-free procedure for the statistical analysis of bioequivalence studies.

D Hauschke1, V W Steinijans, E Diletti.   

Abstract

In bioequivalence assessment, the consumer risk of erroneously accepting bioequivalence is of primary concern. In order to control the consumer risk, the decision problem is formulated with bioinequivalence as hypothesis and bioequivalence as alternative. In the parametric approach, a split into two one-sided test problems and application of two-sample t-tests have been suggested. Rejection of both hypotheses at nominal alpha-level is equivalent to the inclusion of the classical (shortest) (1-2 alpha) 100%-confidence interval in the bioequivalence range. This paper demonstrates that the rejection of the two one-sided hypotheses at nominal alpha-level by means of nonparametric Mann-Whitney-Wilcoxon tests is equivalent to the inclusion of the corresponding distribution-free (1-2 alpha) 100%-confidence interval in the bioequivalence range. This distribution-free (nonparametric) approach needs weaker model assumptions and hence presents an alternative to the parametric approach.

Mesh:

Year:  1992        PMID: 1601530

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  7 in total

1.  Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple subcutaneous administrations.

Authors:  Fritz Sörgel; Ursula Thyroff-Friesinger; Andrea Vetter; Bernhard Vens-Cappell; Martina Kinzig
Journal:  Pharmacology       Date:  2008-12-22       Impact factor: 2.547

2.  Using statistical equivalence testing in clinical biofeedback research.

Authors:  J P Hatch
Journal:  Biofeedback Self Regul       Date:  1996-06

3.  A comparative study of the pharmacokinetics of ibuprofen arginate versus dexibuprofen in healthy volunteers.

Authors:  Belén Sádaba; Miguel A Campanero; Maria Jose Muñoz-Juarez; Isabel Gil-Aldea; Emilio García-Quetglas; Antonio Esteras; Jose R Azanza
Journal:  Eur J Clin Pharmacol       Date:  2006-08-15       Impact factor: 2.953

4.  Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects.

Authors:  R A Smulders; M E Kuipers; W J J Krauwinkel
Journal:  Br J Clin Pharmacol       Date:  2006-08       Impact factor: 4.335

5.  Pharmacokinetic evaluation of a new oral sustained release dosage form of tramadol.

Authors:  H Malonne; B Sonet; B Streel; S Lebrun; S De Niet; A Sereno; F Vanderbist
Journal:  Br J Clin Pharmacol       Date:  2004-03       Impact factor: 4.335

6.  Bioequivalence study of two Ibuprofen formulations administered intravenously in healthy male volunteers.

Authors:  D Chassard; A Geneteau; V Gualano; M Brault
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

7.  Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial.

Authors:  Fritz Sörgel; Ursula Thyroff-Friesinger; Andrea Vetter; Bernhard Vens-Cappell; Martina Kinzig
Journal:  BMC Clin Pharmacol       Date:  2009-05-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.